MacroGenics to Participate in Upcoming Investor Conferences

Rhea-AI Summary

ROCKVILLE, MD, Feb. 6, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on antibody-based therapeutics for cancer, has announced participation in two investor conferences. On February 9, 2023, President & CEO Scott Koenig, M.D., Ph.D., will engage in a fireside chat at the Guggenheim Healthcare Talks in New York. Following this, on February 14, 2023, he will present at the SVB Securities Global Biopharma Conference. Both events will also include one-on-one meetings. Interested parties can access a webcast of these presentations on the MacroGenics Investor Relations website, available for 30 days.

ROCKVILLE, MD, Feb. 06, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following investor conferences in February 2023:

• Guggenheim Healthcare Talks | Oncology Day (New York). MacroGenics’ President & Chief Executive Officer, Scott Koenig, M.D., Ph.D., will participate in a fireside chat on Thursday, February 9, 2023, at 2:45 pm ET.  MacroGenics’ management will also participate in one-on-one meetings.
• SVB Securities Global Biopharma Conference (Virtual). Scott Koenig, M.D., Ph.D., will participate in a formal presentation session with a SVB Securities research analyst on Tuesday, February 14, 2023, at 3:00 pm ET.  MacroGenics’ management will also participate in one-on-one meetings.

A webcast of the above presentations may be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics' website at http://ir.macrogenics.com/events.cfm.  The Company will maintain an archived replay of this webcast on its website for 30 days.   

About MacroGenics, Inc.

MacroGenics (the Company) is a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at www.macrogenics.com. MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc.

###

FAQ

What events is MacroGenics participating in February 2023?

MacroGenics will participate in the Guggenheim Healthcare Talks on February 9, and the SVB Securities Global Biopharma Conference on February 14, 2023.

Who will represent MacroGenics at the investor conferences?

Scott Koenig, M.D., Ph.D., President & CEO of MacroGenics, will represent the company at both conferences.

Where can I watch the MacroGenics presentations from the investor conferences?

The presentations can be accessed via a webcast in the 'Events & Presentations' section of MacroGenics' Investor Relations website.

How long will the webcast of MacroGenics' presentations be available?

The archived replay of the webcasts will be available for 30 days on MacroGenics' website.

What is MacroGenics focused on developing?

MacroGenics is focused on developing innovative antibody-based therapeutics for cancer treatment.